Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
2024年5月3日 - 5:10AM
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or
“Quoin”), a clinical stage specialty pharmaceutical company focused
on rare and orphan diseases, announced today that the Company plans
to release its first quarter 2024 financial results before the
market opens on Thursday, May 9, 2024.
The announcement will provide an operational
update regarding the company’s achievements during the quarter, and
will detail financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage
specialty pharmaceutical company focused on developing and
commercializing therapeutic products that treat rare and orphan
diseases. We are committed to addressing unmet medical needs for
patients, their families, communities and care teams. Quoin’s
innovative pipeline comprises four products in development that
collectively have the potential to target a broad number of rare
and orphan indications, including Netherton Syndrome, Peeling Skin
Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis
Bullosa and others. For more information, visit:
www.quoinpharma.com or LinkedIn for updates.
For further information, contact:Investor
RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com(646)
863-6341
Quoin Pharmaceuticals (NASDAQ:QNRX)
過去 株価チャート
から 4 2024 まで 5 2024
Quoin Pharmaceuticals (NASDAQ:QNRX)
過去 株価チャート
から 5 2023 まで 5 2024